Χώρα: Καναδάς
Γλώσσα: Αγγλικά
Πηγή: Health Canada
FLUOCINONIDE
TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.
D07AC08
FLUOCINONIDE
0.05%
CREAM
FLUOCINONIDE 0.05%
TOPICAL
15/60 GM
Prescription
ANTI-INFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0106313001; AHFS:
APPROVED
2003-09-04
_LYDERM Product Monograph Page 1 of 22 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR LYDERM Fluocinonide Ointment, Gel and Cream, USP 0.05% w/w TOPICAL CORTICOSTEROIDS TAROPHARMA, Date of Initial Authorization: A DIVISION OF TARO PHARMACEUTICALS INC. December 8, 1997 130 East Drive Brampton, Ontario, Canada L6T 1C3 Date of Revision: December 5, 2023 Control #: 267880 _LYDERM Product Monograph Page 2 of 22 _ TABLE OF CONTENTS TABLE OF CONTENTS ..............................................................................................................2 PART I: HEALTH PROFESSIONAL INFOR M ATION..........................................................4 1 INDICATIONS ..................................................................................................................4 2 CONTRAINDICATIONS .................................................................................................4 3 DOSAGE AND ADMINISTRATION .............................................................................4 3.1 Recommended Dose and Dosage Adjustment ...........................................................4 4 OVERDOSAGE .................................................................................................................4 5 DOSAGE FORMS, STRENGTHS, COMPOSITION AND P AC K A G ING ................5 6 WARNINGS AND PRECAUTIONS ...............................................................................6 6.1 Ge ne r al .......................................................................................................................6 6.2 Endocrine and Metabolism ........................................................................................6 6.3 Ophthalmic.................................................................................................................6 6.4 Hepatic .......................................................................................................................6 6.5 Immune ...................................................................... Διαβάστε το πλήρες έγγραφο